The vaccine does not kill cells directly; it primes neoantigen-specific T cells. Activated CD8+ and cytotoxic CD4+ T cells recognize neoantigen peptides (including those presented on HLA class II when expressed by tumor cells) and kill target cells via perforin/granzyme release and Fas–FasL–mediated apoptosis.